Bladder Urothelial Carcinoma Group Research Articles

Diagnostic value of urine cyclic RNA-0071196 for bladder urothelial carcinoma

ObjectiveTo investigate the diagnostic value of urine cyclic RNA-0071196 (circRNA-0071196) in the patients with bladder urothelial carcinoma (BUC).MethodThe expression of circRNA-0071196 was detected in the urine samples using qRT-PCR from 40 BUC patients and 30 non-UBC patients at our department from December 2018 to September 2021. The expression difference of circRNA-0071196 was compared between the two groups, and the relationship between the expression of circRNA-0071196 in the urine of UBC patients and the clinical pathological characteristics was analyzed.Results(1) The expression of circRNA-0071196 in the urine of BUC group was significantly higher than that in the non-BUC group (P < 0.05). (2) The expression of circRNA-0071196 in the urine of BUC group was not related to age, sex, or lymph node metastasis (P > 0.05). (3) The expression of circRNA-0071196 in the urine of BUC group was related to tumor T stage, tumor grade and muscle invasion. (4) The urine circRNA-0071196 expression effectively distinguished BUC patients from non-BUC patients.ConclusionThe elevated expression of urine circRNA-0071196 in BUC patients indicates that circRNA-0071196 has promising potential as a non-invasive urinary biomarker for detecting BUC.

UBC®Rapid Is Sensitive in Detecting High-Grade Bladder Urothelial Carcinoma and Carcinoma in situ in Asian Population

Objectives: Bladder cancer is a common type of malignancy. UBC®Rapid is a novel immunoassay detecting urine cytokeratin 8/18 protein. Studies have shown good accuracy of UBC®Rapid in detecting bladder cancer. UBC®Rapid has however to date not been evaluated in Asian patients. We evaluated UBC®Rapid in detecting Asian bladder cancer, together with urine cytology. Methods: In total, 112 patients were recruited from National University Hospital Singapore and 103 patients were included in this study, comprising 49 patients with bladder urothelial carcinoma (UC), 21 patients with bladder benign lesions, and 33 patients with normal bladder. All the bladder cancer and benign lesions were confirmed by histology. Voided urine was collected for UBC®Rapid test. The results were compared with urine cytology. Results: The bladder UC group had remarkably higher UBC®Rapid value than the control groups. The sensitivity, specificity, positive, and negative predictive value of UBC®Rapid in detecting bladder UC were 53%, 85.5%, 76.5%, and 66.8%, respectively. Those of urine cytology were 40.8%, 96.3%, 90.9%, and 64.2%, respectively. Adding UBC®Rapid to urine cytology increased sensitivity to 57.1% but decreased specificity to 81.8%. UBC®Rapid was sensitive in detecting high-grade bladder UC (61.1%) and carcinoma in situ (CIS) (72.7%), as compared to urine cytology for bladder UC (55.6%) and CIS (54.5%), respectively. Conclusion: UBC®Rapid is sensitive in detecting high-grade bladder UC and CIS in Asian population. It may be useful as an adjunct test to achieve better detection of bladder cancer.

Site-specific differences in survival among upper and lower tract urothelial carcinoma patients treated with radical surgery.

It currently remains unclear whether the location of primary tumours affects the clinical outcomes of patients with locally advanced urothelial carcinoma in the urinary tract. The aim of the present study was to compare prognostic differences between bladder urothelial carcinoma and upper tract urothelial carcinoma, particularly pT3 or higher tumours. In total, 307 patients with pT3 or higher urothelial carcinoma without distant metastasis who underwent radical cystectomy for bladder urothelial carcinoma (N=127, 41.4%) or radical nephroureterectomy for upper tract urothelial carcinoma (N=180, 58.6%) at Keio University Hospital and three affiliated hospitals between 1994 and 2017 were enrolled. Oncological outcomes were compared between bladder urothelial carcinoma and upper tract urothelial carcinoma using Cox regression analysis. Significantly higher rates of male patients, smokers, neoadjuvant chemotherapy, lymph node involvement and lymphovascular invasion were observed in the bladder urothelial carcinoma group. The incidence of regional lymph node or local recurrence was higher in patients with bladder urothelial carcinoma than in those with upper tract urothelial carcinoma, while that of lung metastasis was lower. In all patients, bladder urothelial carcinoma was independently associated with disease recurrence (hazard ratio (HR) 1.504, P=0.035) in addition to neoadjuvant chemotherapy and lymphovascular invasion. Bladder urothelial carcinoma was also independently associated with cancer death (HR=1.998, P=0.002) as well as lymphovascular invasion. Following the exclusion of patients who received neoadjuvant chemotherapy, bladder urothelial carcinoma remained an independent risk factor for disease recurrence and cancer death (HR=1.702, P=0.010 and HR=1.888, P=0.013, respectively). Bladder urothelial carcinoma may follow worse prognosis compared to upper tract urothelial carcinoma, particularly that with a high pathological stage.

Application of urinary proteomics in early diagnosis of bladder urothelial carcinoma

To investigate the difference in urinary proteome between patients with bladder urothelial carcinoma (BUC) and healthy volunteers and to provide a basis for the early diagnosis of BUC. The urine samples from BUC patients and healthy volunteers (controls) were treated by 25% ethanol precipitation and two-dimensional gel electrophoresis (2-DE), and the obtained urinary proteins were subjected to Coomassie brilliant blue staining and analysis by PDQuest 8.0 (2-DE image analysis software); the differentially expressed proteins were sequenced by matrix-assisted laser desorption/ionization time-of-flight/time-of-flight mass spectrometry and identified using the Swiss-Prot database; the differential expression of these proteins was verified by western blot. High-resolution and high-reproducibility 2-DE images were obtained from the urine samples of BUC patients and controls, with 789 ± 18 and 762 ± 14 protein spots, respectively. Compared with the control group, the BUC grouP had significantly decreased expression of 6 protein spots and significantly increased expression of 11 protein spots. The mass spectrometry revealed five proteins with increased expression in the BUC group, including fibrinogen, lactate dehydrogenase B, apolipoprotein A1, clusterin, and haptoglobin, and the results were confirmed by western blot. There is significant difference in urinary proteome between BUC patients and healthy volunteers; the identification of differentially expressed proteins in urine lays the foundation for identifying potential molecular markers in early diagnosis of BUC.

Infiltration related miRNAs in bladder urothelial carcinoma

This study aimed to investigate infiltration related microRNAs (miRNAs) in bladder urothelial carcinoma (BUC). Twenty patients with BUC were enrolled and divided into 2 groups according to infiltration or not: infiltrating BUC group (n=12) and non-infiltrating BUC group (n=8). Gene chip was used to detect infiltration related miRNAs in the BUC samples. In other recruited 17 patients with BUC who were divided into infiltrating BUC samples (n=14) and non-infiltrating BUC samples (n=3), and in 4 BUC cell lines (EJ, 5637, T24 and BIU-87), the expression of miRNAs was assayed by using reverse transcription-polymerase chain reaction (RT-PCR). In infiltrating BUC group, as compared with non-infiltrating BUC group, there were 7 differentially expressed miRNAs: hsa-miR-29c, hsa-miR-200a, hsa-miR-378, hsa-miR-429, hsa-miR-200c and hsa-miR-141 were up-regulated, while hsa-miR-451 was down-regulated. In the BUC samples, the results of RT-PCR were consistent with those by the miRNA array. In the cancer cell lines, RT-PCR in T24 only revealed the similar expression pattern of miRNAs to that by the miRNA array. It is suggested that infiltration of BUC is related with different expression of miRNAs, which may provide a novel platform for further study on function and action mechanism of miRNAs.

Detection, verification and significance of differentially expressed miRNAs in bladder urothelial carcinoma

To explore the differentially expressed miRNAs in bladder urothelial carcinoma (BUC) in order to provide rationales for further studies of function and mechanism for their actions. Fresh normal (5 samples) and BUC (30 samples) tissues were collected from September 2008 to September 2009 in our hospital and analyzed by miRNA microarray to find differentially expressed miRNAs; RT-PCR (reverse transcription-polymerase chain reaction) of recollected samples and 4 types of cell strain to verify the selected miRNAs. In grade I, grade II, grade III, grade I + II + III, infiltrating and non-infiltrating groups, hsa-miR-29b-1 was up-regulated while hsa-miR-923 and hsa-miR-300 were down-regulated. When the infiltrating BUC group was compared with the non-infiltrating BUC group, there were 7 differentially expressed miRNAs. In collected samples, the result of RT-PCR was consistent with that of miRNA array. In 4 types of cancer cell strains, only the result of T24 was completely consistent with that of miRNA array. There are differentially expressed miRNAs between normal bladder mucosa and BUC, infiltration BUC and non-infiltration BUC. The result of T24 cell strain is completely consistent with that of miRNA array.

Detection of cyclooxygenase-2 in serum of patients with bladder urothefial cacinoma

Objective To explore the applied value of quantitative examination of cyclooxygenase2(COX-2)in the serum of patients with bladder urothelial carcinoma(BUC)for diagnosis and follow-up.Methods Serum samples of 95 BUC patients identified by pathology were examined by the quantitative enzyme-linked immunoadsordent assay(EIA).There were 48,39 and 8 cases of WHO grading of G_1,G_2 and G_3,respectively.There were 9,33,25,20 and 8 cases of TNM staging of Tis or Ta,T_1,T_2,T_3 and T_4 respectively.There were 40 cases that underwent surgical procedure previously for BUC but now free by cystoscope of the disease,20 cases of pre-cancerous lesions(including 14 cases of bladder leukoplakia and 6 cases of cystitis glandularis).Thirty-five cases of other urological diseases and 60 healthY volunteers were examined as the matched control groups.Results The level of COX-2 in BUC group was(1.91±0.65)mg/L.significantly higher than other groups.The levels of COX-2 in superficial and invasive BUC were (1.40 ±0.71)and(2.38±1.18)mg/L.The levels of COX-2 in G_1,G_2 and G_3 were(1.29±0.51),(2.13±0.69)and(2.33±0.81)mg/L.respectively.The levels of COX-2 were increased with tumor grade and stage progression.There was no significant difference in the levels of COX-2 between the primary tumors[(1.80±0.81)mg/L]and recurrenttumors[(1.81±1.02)mg/L].Conclusion Serum EIA detection of COX-2 may be a new useful means for diagnosis and postoperative monitoring of BUC patients. Key words: Bladder urothelial carcinoma; COX-2; Diagnosis